Story perspectives

Moderna Shares Drop 25% After Melanoma Vaccine Data Leak

By Drooid · Oct 22, 2026, 10:03 PM UTC · How we work

Summary

Story summary

Moderna’s shares dropped about 25% after a leak of melanoma vaccine data.
The intismeran autogene-Keytruda combo cut recurrence or death risk by 42%.
It lowered distant metastasis or death risk by 38% versus Keytruda alone.
At two years 82% of patients on the combo were recurrence-free versus 70% on Keytruda.

1 of 1

Story summary

Moderna’s shares dropped about 25% after a leak of melanoma vaccine data.
The intismeran autogene-Keytruda combo cut recurrence or death risk by 42%.
It lowered distant metastasis or death risk by 38% versus Keytruda alone.
At two years 82% of patients on the combo were recurrence-free versus 70% on Keytruda.